On January 12, H.C. Wainwright adjusted its price target for Nuvation Bio Inc. (NUVB), lowering it to $17 from $18. The firm maintained its Buy rating on the stock. It stated that the company's fourth-quarter sales for IBTROZI met expectations.
Nuvation Bio released preliminary figures on the same day. The company reported approximately $15.7 million in net product revenue for IBTROZI (taletrectinib) for the fourth quarter of 2025. During this period, 216 new patients began treatment with the drug.
The company also confirmed it received a $25 million milestone payment from Nippon Kayaku. Nuvation Bio is a clinical-stage biopharmaceutical company. Its lead asset, IBTROZI, is developed for oncology patients, targeting rare and difficult-to-treat cancers.
The company's focus remains on precision medicine and expanding its pipeline. It aims to improve outcomes for patients who have limited therapeutic options available.